3D Systems (DDD) Q4 2024 earnings summary

Executive summary

• Full-year 2024 revenue reached $440 million, within guidance, despite a $9 million Q4 reduction from a change in accounting estimate for the regenerative medicine program.

• Strong Q4 industrial printer sales and global services growth, with Application Innovation Group revenues up 18% for FY'24.

• Aggressive cost reduction and restructuring actions targeting over $50 million in annualized savings by mid-2026, including site closures and headcount reductions.

• Announced sale of Geomagic software platform for $123 million, expected to close in early Q2 2025, with proceeds to strengthen liquidity.

• Strategic focus remains on healthcare and industrial segments, with dental applications highlighted as a major growth opportunity, supported by FDA clearance and new product launches.

Financial highlights

• Q4 2024 consolidated revenue was $111 million, down 3% year-over-year, primarily due to the $9 million accounting change.

• Full-year 2024 revenue was $440 million, a 10% decline from the prior year, mainly from weaker printer sales.

• Q4 non-GAAP gross margin was 31.3% (down from 39.8% prior year); full-year non-GAAP gross margin was 37.4% (down from 40.6%).

• Adjusted EBITDA for Q4 was negative $19.1 million; full-year adjusted EBITDA was negative $66.4 million.

• Ended 2024 with $171 million in cash and cash equivalents, with significant debt repurchases improving the balance sheet.

Outlook and guidance

• 2025 revenue guidance is $420–$435 million, representing flat to modest growth after excluding Geomagic revenue.

• Non-GAAP gross margin expected in the 37–39% range, with operating expenses of $200–$220 million.

• Adjusted EBITDA is expected to improve each quarter in 2025, with break-even or better by Q4.

• Cost reduction actions are expected to drive significant profitability improvements even in a flat sales environment.

• Macro and geopolitical uncertainty expected to persist, impacting top-line growth.